NRD
CATX icon

Nebula Research & Development’s Perspective Therapeutics CATX Stock Holding History

Nebula Research & Development’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10,770
Closed -$22.9K – 974
2025
Q1 		$22.9K Sell
10,770
-11,080
-51% -$33.3K ﹤0.01% 925
2024
Q4 		$69.7K Buy
21,850
+7,007
+47% +$57.2K 0.01% 866
2024
Q3 		$198K Buy
+14,843
New +$197K 0.02% 828

Other funds holding CATX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NWMG
Nicholson Wealth Management Group Charlestown, South Carolina $172M AUM 10.38% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nebula Research & Development's CATX Position: Q2 2025 in Review

Nebula Research & Development sold out of Perspective Therapeutics (CATX) in Q2 2025, closing a stake of 10,770 shares — an estimated $22.9K sold.

Nebula Research & Development first reported a position in CATX in Q3 2024 and held it in 3 quarters. The position peaked at $198K in Q3 2024. 97 funds tracked by Wall St. Rank hold CATX as of Q2 2025.

  • Nebula Research & Development reported no remaining Perspective Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Nebula Research & Development sold 10,770 Perspective Therapeutics shares in Q2 2025, an estimated $22.9K.
  • Nebula Research & Development first reported a position in Perspective Therapeutics in Q3 2024 and held it in 3 quarters.
  • Nebula Research & Development's Perspective Therapeutics position peaked at $198K in Q3 2024.
  • 97 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q2 2025.

Based on Nebula Research & Development's 13F filing for Q2 2025, filed 14 Aug 2025.